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Abstract: Exenatide is a GLP-1 receptor agonist approved for use in type 2 diabetes mellitus. 
In clinical trials, significant reductions in serum glucose and weight were demonstrated for 
exenatide with primary glycemic effects of the twice daily formulation on prandial glucose 
control. In this paper, we review recent research with exenatide as adjunctive therapy in type 2 
diabetes mellitus. In particular, studies demonstrate ongoing benefit on glycemic control and 
weight reduction with continued therapy up to 82 weeks duration and efficacy as adjunctive 
therapy for patients taking metformin, thiazolidinediones, and/or a sulfonylurea and as compared 
to sitagliptin and various insulin formulations. Compared to insulin, exenatide likely has greatest 
benefit for those patients who are overweight or who need improved prandial glucose control. 
The new long-acting release formulation of exenatide has demonstrated slightly improved efficacy 
compared to the twice daily formulation as well as a reduction in gastrointestinal side effects. 
Emerging research is further exploring novel benefits of exenatide as adjunctive DM therapy, 
effects on prandial glycemic control, markers of hepatic inflammation, alternative dosage forms 
including intra-nasal administration, and effects on beta cell function.
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Background
The prevalence of diabetes mellitus is conservatively estimated at 23 million individu-
als in the United States.1 Weight gain is directly correlated with insulin resistance 
and predisposes to the development of type 2 diabetes mellitus (T2DM), so it is not 
surprising that the increasing incidence of this disorder mirrors the epidemic rise in 
obesity among US citizens. Health care costs related to the treatment of diabetes and its 
complications are staggering, estimated at US$116 billion annually.1 The development 
of diabetes associated microvascular complications can be reduced by the improvement 
in hyperglycemia associated with the condition.2,3 Since 1995, therapeutic options 
for the treatment of T2DM have grown considerably. Unfortunately this increase in 
pharmacologic choices has not translated into an improvement in individual glycemic 
targets associated with a reduction in diabetic microvascular complications.4 One of 
the hurdles to improving hyperglycemia is patient adherence to a prescribed medical 
regimen. Often patients cite a reluctance to gain weight, a common side effect of many 
available hypoglycemic medications. Therapies that effectively reduce blood glucose 
and are weight neutral or can promote weight loss are highly sought.
Insulin secretion is more pronounced in response to an oral glucose stimulus 
compared to a calorically equivalent intravenous glycemic bolus, a phenomenon 
termed the incretin effect.5 This effect, presumed to be the result of a coordinated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 136
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interplay between gut hormones and pancreatic islet cells, 
can account for up to 70% of postprandial insulin production. 
Many intestinal hormones can stimulate insulin secretion, 
however studies suggest that two gut hormones, glucagon 
like peptide 1 (GLP-1) and glucose dependent insulinotropic 
polypeptide (GIP) are predominantly responsible for the 
incretin effect( 6). Specifically GLP-1 and GIP are secreted 
following a meal, augment insulin secretion, and their insu-
linotropic effect is only seen during times of hyperglycemia. 
Interference with incretin hormone activity is associated with 
reduced insulin secretion and hyperglycemia.7,8 The actions 
of incretin hormones would suggest an ideal pharmacologic 
agent for the treatment of hyperglycemia. Despite these 
factors, administration of GIP to individuals with T2DM 
has little hyperglycemia ameliorating effect even when 
given in supraphysiologic doses.9 Studies have shown that 
hyperglycemia down regulates GIP receptors on the beta cell 
thus reducing the potential for GIP as a therapeutic agent.10 In 
comparison, GLP-1 administration to individuals with T2DM 
is associated with a response predicted by the administration 
of an incretin hormone and has been intensely studied as a 
therapeutic agent in T2DM.
GLP-1 is derived from cleavage of the larger polypeptide, 
proglucagon, the precursor to related compounds, GLP-2, 
glucagon, oxyntomodulin and glicentin.11 Production and 
secretion of GLP-1 occurs in the enteroendocrine L-cells 
of the jejunum and ileum. GLP-1 plasma levels are low in 
the fasting state but rise significantly in response to meal 
ingestion.12 Certain nutrient types can be more stimulatory, 
however the exact factors leading to GLP-1 production and 
secretion are still not known.12,13
GLP-1 administration to individuals with and without DM 
is associated with an augmentation of insulin secretion and 
activity14 as well as a concomitant inhibition of post-meal 
glucagon production.15 This coordinated islet cell hormone 
production is ideally suited to reduce meal-induced hyper-
glycemia. Even more salutary is that this function is glucose 
dependent, predominating only during times of elevated serum 
glucose, therefore GLP-1 is less likely to induce hypoglycemia. 
Beyond its glucose regulatory effect, GLP-1 has exhibited 
CNS appetite control, promoting satiety and decreased GI 
motility.16 Individuals with T2DM or impaired glucose 
tolerance exhibit reduced GLP-1 serum levels in response 
to a meal.17,18 Moreover GLP-1 secretion post prandially is 
inversely correlated with the degree of insulin resistance.19 
In summary, GLP-1 promotes glucose dependent insulin 
secretion, decreases post-meal glucagon production, inhibits 
gastric motility, promotes satiety and is deficient in those with 
T2DM, making it an ideal pharmacologic agent. Enthusiasm 
for this concept waned with the realization that GLP-1 is 
rapidly metabolized following secretion in sera. GLP-1 is 
inactivated by cleavage at the position 2 alanine residue by 
the endopeptidase dipeptidyl peptidase 4 (DPP 4).20,21 DPP 4 
removes two amino acids from the N-terminus residue of 
GLP-1, a process that inactivates the insulinotropic effect. 
DPP 4 is secreted from capillary endothelial cells and can 
quickly and effectively metabolize GLP-1. The half-life of 
endogenous GLP-1 is 1 to 2 minutes.21 Clearly any attempt 
to utilize these agents pharmacologically would mandate the 
abrogation of DPP 4 metabolism.
Exendin 4 is a naturally occurring 39 amino acid GLP-1 
receptor agonist originally isolated in the saliva of the Gila 
Monster (Heloderma suspectum).22 The peptide has 53% 
homology with mammalian GLP-1 with similar incretin 
hormone physiology.22,23 The compound is more resistant 
to DPP 4 metabolism and therefore has a much longer half-
life. Exenatide (Byetta®; Amylin Pharmaceuticals, Inc., and 
Lilly USA, LLC), a synthetic analogue of exendin 4, was 
approved by the FDA for use in the treatment of T2DM on 
April 28, 2005.24 Exenatide has a half-life of 2 hours when 
administered subcutaneously. Clinical trials designed to 
evaluate the glycemic effects of exenatide, either as a solo 
agent or in combination with other hypoglycemic medica-
tions, have proven its efficacy to lower serum glucose and 
promote weight loss. Exenatide is administered as a 5 µg or 
10 µg dose subcutaneously twice daily.
Among individuals with poorly controlled T2DM on 
maximal sulfonylurea or metformin therapy, or the combina-
tion, exenatide administered in 5 µg or 10 µg subcutaneous 
twice daily dosing was associated with a significant hemo-
globin A1c (HbA1c) reduction and weight loss compared to 
placebo at 30 weeks.25–27 Those individuals randomized to 
receive 10 µg twice daily, experienced an average HbA1c 
reduction of 0.9% with an associated average weight loss of 
1.6 kg. Approximately 40% of the individuals with a baseline 
HbA1c of 8.3% attained HbA1c values 7% at study closure. 
Overall exenatide was well tolerated with the most common 
side effect being nausea that occurred in a significant minority 
of individuals but was self limited in the vast majority. Due 
to the gastrointestinal side effects, it is recommended that 
exenatide be initiated at a 5 µg twice daily dose with titration 
to 10 µg twice daily after one month. In some individuals, 
gastrointestinal side effects may be limited by administration 
10 to 15 minutes prior to a meal. Hypoglycemia was rare in 
these studies, was most often associated with concomitant 
sulfonylurea use and abrogated by a decrease in sulfonylurea Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 137
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dosing. A summary of the initial clinical trial experience with 
exenatide can be found in Table 1.
Since the initial release of exenatide, research has 
continued to explore the long-term effects, efficacy as adjunc-
tive therapy, and to further tease out any pharmacokinetic 
distinctions in special populations or drug interactions. The 
following is a summary of the clinical trial research evalu-
ating long-term use and comparative efficacy of exenatide 
published in the last three years since publication of the initial 
exenatide trials and its release to the US market.
Methods
Data sources
A MEDLINE search (January 2006–April 2009) was 
conducted with the key words exenatide and Byetta for 
clinical trials limited to human research published in 
English. Follow-up searches were performed using key 
author names. References of identified articles were used 
for additional citations. BIOSIS Previews and the American 
Diabetes Association 2008 Scientific Abstracts were used for 
published abstract information.
Study selection and data extraction
Clinical trials (prospective, randomized, controlled trials) 
evaluating the safety and efficacy of exenatide as adjunc-
tive therapy for T2DM in adults and children were selected. 
Data presented at 2008 diabetes scientific meetings of the 
American Diabetes Association and the American Associa-
tion of Clinical Endocrinologists and available in abstract 
format were included for timeliness and are outlined in the 
‘Emerging Research’ section.
Results
There were 8 (exenatide) adjunctive therapy clinical trials 
published between January 1, 2006 and April 30, 2009, 
including one major report of continuation of the initial three 
exenatide clinical trials.25–27 Three abstracts were published 
in 2008 presenting clinical trial research.
Clinical trials
In the last 3 years, exenatide has been evaluated in open label 
extension trials, as a once weekly formulation, as adjunctive 
therapy with metformin, sulfonylureas, and/or thiazolidin-
ediones, and as compared to sitagliptin and insulin.
extension studies
Several studies28–30 have reported the results stemming from 
an interim (82 week) evaluation of extension of therapy in 
the three initial multicenter, double-blind, placebo controlled 
efficacy trials.25–27 The most recent report details findings 
from a 24-month pooled interim analysis of this real world 
extension of exenatide, highlighting the effects on HbA1c, 
liver function, and weight.31 Following completion of the 
30-week clinical trials,25–27 974 subjects opted to continue 
open label use of exenatide, however, 453 were excluded 
due to site closure or late enrollment. Of the 521 remaining 
subjects considered to be the 2-year eligible intention to treat 
group, 283 subjects completed the full 2 years of treatment for 
Table 1 Summary of initial exenatide clinical trials
Study SFU + exenatide or placebo25  Met + exenatide  
or placebo26
Met/SFU + exenatide  
or placebo27
   Exenatide  
10 µg bid
Placebo  Exenatide 
10 µg bid
Placebo  Exenatide 
10 µg bid
Placebo
Subjects (N) 129 123 113 113 241 247
HbA1c decrease (avg) -0.86% 
(P  0.001)
+0.12% -0.78% 
(P  0.002)
+0.08% -0.8% 
(P  0.0001)
+0.2
7% HbA1c (%) 41%  
(P  0.0002)
8.8% 46% 
(p  0.01)
13% 34% 
(P  0.0001)
9%
wt loss (Avge kg) -1.6 (P  0.05), 
baseline 97 kg
-0.6 -2.8  
(P  0.001), 
100 kg 
baseline
-0.3 -1.6 
(P  0.01), 
98 kg baseline
-0.9
Nausea (%) 51% 7% 45% 23% 49% 21%
Mild to moderate 
hypoglycemia  60 mg/dL
36% 3% 5% 5% 28% 13%
Severe hypoglycemia 0% 0% 0% 0% 0% 0%
Abbreviations: SFU, sulfonylurea; Met, metforminDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 138
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the interim analysis (238 withdrew from study due to adverse 
event 9%, loss of glucose control 3%, loss to follow-up 5%, 
administrative, investigator decision or protocol violation 
14%, or withdrawal of consent 15%). The initial reduction 
in HbA1c (-0.9%) seen in the pooled analysis of the 3 clinical 
trials was sustained at 2 years (-1.1%, P  0.001, 2-year 
completer population) and was significantly lower than 
baseline. In addition, weight reduction (mean [SD]) was 
progressive with continuation therapy (-2.1 kg [0.2] at 
30 weeks to -4.7 kg [0.3] at 2 years, P  0.001, and BMI 
reduction of 1.6 kg/m2 [0.1], P  0.001, vs baseline for 
2-year completer population). Of note, subjects with slightly 
elevated ALT at baseline (mean 38 (SEM 1) IU/mL, 53% 
of the sample) had a significant mean reduction from base-
line (-11 (SEM 1) IU/mL, P  0.05), with 39% achieving 
a normal ALT by 104 weeks. These findings support the 
ongoing use of exenatide for diabetes and weight control, 
and highlight a potential therapeutic option for those who are 
overweight with elevated ALT, to improve liver function.
Once weekly formulation
The use of exenatide may be deferred by some patients taking 
oral diabetes medications in an effort to avoid the use of 
injections. Recent research has explored the option of a once 
weekly formulation of exenatide as a less frequently adminis-
tered alternate to twice daily injections. In a phase 2, placebo 
comparison study, long-acting release (LAR) exenatide 
(0.8 mg and 2 mg) was studied in adults with T2DM (N = 45, 
baseline HbA1c 8.3% to 8.6% across groups) with or without 
metformin (n = 27 using metformin).32 By week 2, exenatide 
levels had achieved the desired minimal concentration for 
effect (50 pg/mL). Fasting plasma glucose was significantly 
reduced at week 15 (-43.2 ± 16.2 and -39.6 ± 9 mg/dL as 
computed from mmol/L reported for the 0.8 mg and 2 mg 
groups, respectively, P  0.001 vs placebo). The magnitude 
of postprandial glucose excursion was reduced by a factor of 
4 for the 2 mg exenatide LAR group compared to placebo. 
HbA1c was reduced by 1.4% (±0.3) and 1.7% (±0.3) for the 
0.8 (N = 16) and 2 mg (N = 15) dose groups, respectively, 
with 36% of subjects in the 0.8 mg group and 86% in the 
2 mg group achieving HbA1c  7% at week 15, compared 
with 0% of placebo subjects (N = 14). Additionally, patients 
in the 2 mg group achieved a 3.8 kg weight loss (±1.4 kg) 
or 3.5% of baseline body weight at 15 weeks (P  0.05). 
Body weight was unchanged from baseline for the 0.8 mg 
and placebo LAR groups. In a study reported by Drucker and 
colleagues, LAR exenatide 2 mg given subcutaneously (SC) 
once weekly was compared to 10 µg exenatide SC twice daily 
in an open-label, non-inferiority study in 295 people with 
T2DM either naïve to treatment or on 1 or more antidiabetic 
medications.33 At 30 weeks, the once weekly exenatide 
group had a greater reduction in HbA1c (-1.9% vs -1.5%, 
P = 0.0023) and a greater proportion of patients achieved an 
HbA1c  7% (77% in weekly group vs 61% in BID group, 
P = 0.0039). Fasting plasma glucose was reduced to a greater 
extent (-41.4 [SE 3.6] mg/dL vs -25.2 [3.6], P  0.0001), 
for once weekly and twice daily, respectively. Weight loss 
was similar for the two treatment groups. Nausea, the most 
common side effect seen with the twice daily formulation 
currently available, was reported by 26.4% of subjects 
receiving the once weekly formulation as compared to 
34.5% of the twice daily group with vomiting rates of 10.8% 
for once weekly and 18.6% for twice daily administration. 
Injection site pruritus was reported to a much greater extent 
(17.6% vs 1.4%) by the group receiving the once weekly 
formulation. The improved reduction in HbA1c seen with the 
weekly formulation is likely related to the longer duration 
of action allowing for ongoing incretin supplementation 
rather than the shorter, burst supplementation provided by 
the twice daily formulation which has a half-life of 2 hours 
resulting in loss of coverage between doses. Patient reported 
side effects (eg, nausea or bloating) are also less likely with 
the weekly formulation, possibly related to reduction of 
daily peak effects.34 The use of a once weekly formulation 
presents a promising new option for those who may benefit 
from incretin therapy.
Adjunctive therapy comparative trials
Exenatide has recently been evaluated as adjunctive 
therapy with metformin, thiazolidinediones, sulfonylureas, 
or combinations of these and compared with insulin and 
sitagliptin (Table 2). Overall, the addition of exenatide is 
beneficial with greatest potential in those who are overweight 
or with prandial glucose excursions not responding to oral 
therapy or insulin.
exenatide vs insulin
Whether to initiate exenatide or insulin in an individual with 
uncontrolled T2DM is a decision based on several factors 
including the need for weight loss, needs for prandial versus 
basal glucose control, co-morbidities (eg, exenatide contra-
indication if motility disorders) and patient acceptance of 
injection therapy. From a pharmacologic standpoint, basal 
insulin and exenatide therapies are quite different. The usual 
first step in insulin therapy in T2DM, basal insulin, targets 
overall control, as measured by fasting plasma glucose, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 139
exenatide adjunctive therapy for type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
2
 
C
o
m
p
a
r
a
t
i
v
e
 
s
t
u
d
i
e
s
 
o
f
 
e
x
e
n
a
t
i
d
e
 
a
s
 
a
d
j
u
n
c
t
i
v
e
 
t
h
e
r
a
p
y
 
i
n
 
a
d
u
l
t
s
 
w
i
t
h
 
t
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
m
e
l
l
i
t
u
s
P
r
i
m
a
r
y
 
i
n
v
e
s
t
i
g
a
t
o
r
C
o
m
p
a
r
a
t
o
r
 
t
o
 
e
x
e
n
a
t
i
d
e
a
A
d
j
u
n
c
t
i
v
e
 
D
M
 
t
x
T
r
i
a
l
 
d
e
s
i
g
n
S
u
b
j
e
c
t
s
 
c
o
m
b
i
n
e
d
 
b
a
s
e
l
i
n
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
O
u
t
c
o
m
e
s
R
e
s
u
l
t
s
O
f
 
n
o
t
e
…
D
a
v
i
s
3
6
I
n
s
u
l
i
n
 
(
p
a
t
i
e
n
t
’
s
 
p
r
e
-
s
t
u
d
y
 
r
e
g
i
m
e
n
)
M
e
t
f
o
r
m
i
n
 
a
n
d
/
o
r
 
S
F
U
1
6
-
w
e
e
k
,
 
o
p
e
n
-
l
a
b
e
l
,
 
2
:
1
 
r
a
n
d
o
m
i
z
e
d
 
r
e
p
l
a
c
e
m
e
n
t
 
o
f
 
i
n
s
u
l
i
n
 
w
i
t
h
 
e
x
e
n
a
t
i
d
e
N
 
=
 
5
1
,
 
5
3
 
y
r
s
,
 
B
M
I
 
3
4
,
 
H
b
A
1
c
 
8
.
1
%
,
 
D
M
 
×
 
1
1
 
y
r
s
H
b
A
1
c
 
i
n
c
r
e
a
s
e
 

 
0
.
5
%
H
b
A
1
c
 
c
h
a
n
g
e
s
 
n
o
t
 
s
i
g
.
 
d
i
f
f
e
r
e
n
t
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
;
 
6
2
%
 
e
x
e
n
a
t
i
d
e
 
v
s
 
8
1
%
 
i
n
s
u
l
i
n
-
t
r
e
a
t
e
d
 
p
a
t
i
e
n
t
s
 
m
a
i
n
t
a
i
n
e
d
 
g
l
y
c
e
m
i
c
 
c
o
n
t
r
o
l
H
y
p
o
g
l
y
c
e
m
i
a
 
i
n
c
i
d
e
n
c
e
 
3
9
%
 
e
x
e
n
a
t
i
d
e
 
a
n
d
 
3
8
%
 
i
n
s
u
l
i
n
,
 
p
r
i
m
a
r
i
l
y
 
d
u
r
i
n
g
 
d
a
y
t
i
m
e
 
a
n
d
 
i
n
 
t
h
o
s
e
 
u
s
i
n
g
 
a
 
S
F
U
B
a
r
n
e
t
t
3
7
i
n
s
u
l
i
n
 
g
l
a
r
g
i
n
e
 
t
i
t
r
a
t
e
d
 
t
o
 
f
a
s
t
i
n
g
 
s
e
r
u
m
 
g
l
u
c
o
s
e
 
1
0
0
 
m
g
/
d
L
S
i
n
g
l
e
 
a
g
e
n
t
 
u
s
i
n
g
 
e
i
t
h
e
r
 
m
e
t
f
o
r
m
i
n
 
o
r
 
S
F
U
2
 
×
 
1
6
-
w
e
e
k
,
 
o
p
e
n
 
l
a
b
e
l
,
 
c
r
o
s
s
-
o
v
e
r
,
 
n
o
n
-
i
n
f
e
r
i
o
r
i
t
y
,
 
r
a
n
d
o
m
i
z
e
d
N
 
=
 
1
3
8
,
 
5
4
.
9
 
y
r
s
,
 
B
M
I
 
3
1
,
 
H
b
A
1
c
 
8
.
9
%
,
 
D
M
 
×
 
7
.
4
 
y
r
s
,
 
5
5
.
1
%
 
m
e
t
f
o
r
m
i
n
,
 
4
4
.
9
%
 
S
F
U
C
h
a
n
g
e
 
i
n
 
H
b
A
1
c
H
b
A
1
c
 
r
e
d
u
c
t
i
o
n
 
1
.
3
6
%
 
b
o
t
h
 
g
r
o
u
p
s
,
 
b
o
t
h
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
l
o
w
e
r
 
t
h
a
n
 
b
a
s
e
l
i
n
e
 
 
(
P
 

 
0
.
0
0
1
)
e
x
e
n
a
t
i
d
e
 
p
r
o
d
u
c
e
d
 
l
o
w
e
r
 
2
-
h
 
P
P
G
 
e
x
c
u
r
s
i
o
n
s
 
t
h
a
n
 
i
n
s
u
l
i
n
 
(
P
 

 
0
.
0
1
6
)
.
 
 
N
a
u
s
e
a
 
g
r
e
a
t
e
r
 
f
o
r
 
e
x
e
n
a
t
i
d
e
 
(
4
2
.
6
%
 
v
s
 
3
.
1
%
)
,
 
h
o
w
e
v
e
r
,
 
h
y
p
o
g
l
y
c
e
m
i
a
 
w
a
s
 
n
o
 
d
i
f
f
e
r
e
n
t
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
N
a
u
c
k
3
8
B
i
p
h
a
s
i
c
 
i
n
s
u
l
i
n
 
a
s
p
a
r
t
 
(
B
I
a
s
p
)
 
7
0
/
3
0
 
t
i
t
r
a
t
e
d
 
t
o
 
f
a
s
t
i
n
g
 
g
l
u
c
o
s
e
 

1
2
6
 
m
g
/
d
L
 
a
n
d
 
2
 
h
o
u
r
 
p
o
s
t
p
r
a
n
d
i
a
l
 

1
8
0
 
m
g
/
d
L
M
e
t
f
o
r
m
i
n
 
a
n
d
 
S
F
U
5
2
-
w
e
e
k
,
 
o
p
e
n
 
l
a
b
e
l
,
 
n
o
n
i
n
f
e
r
i
o
r
i
t
y
 
t
r
i
a
l
N
 
=
 
4
4
6
,
 
5
8
.
5
 
y
r
s
,
 
B
M
I
 
3
0
,
 
H
b
A
1
c
 
8
.
6
%
,
 
D
M
 
d
u
r
a
t
i
o
n
 
×
 
1
0
 
y
r
s
H
b
A
1
c
 
d
i
f
f
e
r
e
n
c
e
 

 
0
.
4
%
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
E
x
e
n
a
t
i
d
e
 
d
e
m
o
n
s
t
r
a
t
e
d
 
n
o
n
-
i
n
f
e
r
i
o
r
i
t
y
 
t
o
 
p
r
e
m
i
x
e
d
 
i
n
s
u
l
i
n
W
i
t
h
d
r
a
w
a
l
 
r
a
t
e
 
2
1
%
 
e
x
e
n
a
t
i
d
e
 
v
s
 
1
0
%
 
i
n
s
u
l
i
n
 
d
u
e
 
t
o
 
p
r
o
t
o
c
o
l
 
v
i
o
l
a
t
i
o
n
s
 
a
n
d
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
B
e
r
g
e
n
s
t
a
l
3
9
B
I
a
s
p
 
7
0
/
3
0
 
fi
x
e
d
 
d
o
s
e
 
o
f
 
1
2
 
u
n
i
t
s
 
o
n
c
e
 
d
a
i
l
y
 
b
e
f
o
r
e
 
s
u
p
p
e
r
 
o
r
 
1
2
 
u
n
i
t
s
 
t
w
i
c
e
 
d
a
i
l
y
 
g
i
v
e
n
 
b
e
f
o
r
e
 
b
r
e
a
k
f
a
s
t
 
a
n
d
 
s
u
p
p
e
r
M
e
t
f
o
r
m
i
n
 
a
n
d
 
S
F
U
2
4
-
w
e
e
k
,
 
o
p
e
n
 
l
a
b
e
l
,
 
r
a
n
d
o
m
i
z
e
d
 
1
:
1
:
1
N
 
=
 
3
7
2
,
 

 
1
8
 
y
r
s
 
o
f
 
a
g
e
,
 
H
b
A
1
c
 
1
0
.
2
%
,
 
D
M
 
d
u
r
a
t
i
o
n
 
9
 
y
r
s
H
b
A
1
c
,
 
F
P
G
,
 
s
a
f
e
t
y
H
b
A
1
c
 
r
e
d
u
c
t
i
o
n
 
0
.
9
1
%
 
b
i
d
 
g
r
o
u
p
,
 
r
e
d
u
c
t
i
o
n
 
0
.
6
7
%
 
q
d
 
g
r
o
u
p
.
 
H
b
A
1
c
 

 
6
.
5
%
 
a
c
h
i
e
v
e
d
 
b
y
 
2
5
%
 
b
i
d
 
v
s
 
8
%
 
e
x
e
n
a
t
i
d
e
,
 
P
 
=
 
0
.
0
0
0
4
H
y
p
o
g
l
y
c
e
m
i
a
 
5
6
%
,
 
6
1
%
,
 
a
n
d
 
2
9
%
,
 
d
a
i
l
y
 
B
I
a
s
p
,
 
b
i
d
 
B
I
a
s
p
,
 
a
n
d
 
e
x
e
n
a
t
i
d
e
,
 
r
e
s
p
e
c
t
i
v
e
l
y
.
 
w
e
i
g
h
t
 
+
2
.
8
5
 
k
g
,
 
+
4
.
0
8
 
k
g
,
 
–
1
.
9
6
 
k
g
 
f
o
r
 
d
a
i
l
y
 
i
n
s
u
l
i
n
,
 
b
i
d
 
i
n
s
u
l
i
n
,
 
a
n
d
 
e
x
e
n
a
t
i
d
e
,
 
r
e
s
p
e
c
t
i
v
e
l
y
G
l
a
s
s
4
0
G
l
a
r
g
i
n
e
 
o
r
 
b
i
p
h
a
s
i
c
 
i
n
s
u
l
i
n
 
a
s
p
a
r
t
 
(
B
I
a
s
p
)
M
e
t
f
o
r
m
i
n
 
a
n
d
 
S
F
U
P
o
o
l
e
d
,
 
p
o
s
t
-
h
o
c
 
a
n
a
l
y
s
i
s
 
o
f
 
2
N
 
=
 
1
0
4
7
H
b
A
1
c
,
 
w
e
i
g
h
t
2
2
%
 
a
c
h
i
e
v
e
d
 
5
%
 
o
r
 
m
o
r
e
 
w
e
i
g
h
t
 
l
o
s
s
;
 
3
.
2
%
 
a
c
h
i
e
v
e
d
 
1
0
%
 
o
r
 
m
o
r
e
;
 
7
3
.
3
%
 
a
v
e
r
a
g
e
d
 
3
 
k
g
 
w
e
i
g
h
t
 
l
o
s
s
 
o
n
 
e
x
e
n
a
t
i
d
e
 
v
s
 
2
%
 
a
t
 
l
e
a
s
t
 
5
 
k
g
 
w
e
i
g
h
t
 
l
o
s
s
;
 
0
.
2
%
 
a
t
 
l
e
a
s
t
 
1
0
%
 
w
e
i
g
h
t
 
l
o
s
s
;
 
a
n
d
 
7
5
.
9
%
 
m
e
a
n
 
3
 
k
g
 
g
a
i
n
 
f
o
r
 
i
n
s
u
l
i
n
 
g
r
o
u
p
S
i
m
i
l
a
r
 
g
l
y
c
e
m
i
c
 
c
o
n
t
r
o
l
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
S
c
h
w
a
r
t
z
4
1
P
l
a
c
e
b
o
M
e
t
f
o
r
m
i
n
 
w
i
t
h
 
(
3
7
%
)
 
o
r
 
w
i
t
h
o
u
t
 
(
6
3
%
)
 
a
 
T
Z
D
2
-
w
e
e
k
,
 
r
a
n
d
o
m
i
z
e
d
,
 
d
o
u
b
l
e
-
b
l
i
n
d
,
 
2
-
a
r
m
,
 
p
a
r
a
l
l
e
l
-
g
r
o
u
p
,
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
N
 
=
 
3
0
,
 
6
3
%
 
f
e
m
a
l
e
,
 
5
3
 
y
r
s
,
 
B
M
I
 
3
4
,
 
H
b
A
1
c
 
8
%
,
 
D
M
 
d
u
r
a
t
i
o
n
 
8
.
7
 
y
r
s
,
 
6
0
%
 
H
i
s
p
a
n
i
c
,
 
W
h
i
t
e
 
3
3
%
,
 
B
l
a
c
k
 
7
%
G
l
u
c
o
s
e
 
o
v
e
r
 
2
4
-
h
,
 
p
r
e
-
 
a
n
d
 
p
o
s
t
p
r
a
n
d
i
a
l
 
t
r
i
g
l
y
c
e
r
i
d
e
s
 
a
n
d
 
f
a
t
t
y
 
a
c
i
d
s
2
4
-
h
 
m
e
a
n
 
g
l
u
c
o
s
e
 
1
2
6
 
m
g
/
d
L
 
(
±
3
.
6
)
 
a
n
d
 
1
5
7
 
m
g
/
d
L
 
(
±
5
.
4
)
 
f
o
r
 
e
x
e
n
a
t
i
d
e
 
a
n
d
 
p
l
a
c
e
b
o
,
 
r
e
s
p
e
c
t
i
v
e
l
y
 
(
P
 

 
0
.
0
0
1
)
;
 
a
l
l
 
2
-
h
 
p
o
s
t
p
r
a
n
d
i
a
l
 
p
o
i
n
t
s
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
r
e
d
u
c
e
d
 
f
o
r
 
e
x
e
n
a
t
i
d
e
;
 
t
r
i
g
l
y
c
e
r
i
d
e
 
i
n
c
r
e
a
s
e
s
 
w
e
r
e
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
l
o
w
e
r
 
p
o
s
t
-
m
e
a
l
 
a
f
t
e
r
 
2
 
w
e
e
k
s
 
o
f
 
e
x
e
n
a
t
i
d
e
;
 
n
o
 
e
f
f
e
c
t
 
o
f
 
f
r
e
e
 
f
a
t
t
y
 
a
c
i
d
s
e
x
e
n
a
t
i
d
e
 
t
i
t
r
a
t
i
o
n
 
o
c
c
u
r
r
e
d
 
d
u
r
i
n
g
 
t
h
e
 
2
-
w
e
e
k
 
s
t
u
d
y
 
p
h
a
s
e
(
C
o
n
t
i
n
u
e
d
)Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 140
Odegard and DeSantis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
whereas exenatide has a greater impact on reducing prandial 
glucose excursions. Ideally, decisions about which product 
to initiate should be made with the specific needs for glucose 
control in mind. This point is reinforced by an earlier 2005 
study comparing the addition of exenatide or insulin glargine 
in 551 subjects suboptimally controlled on metformin and 
a sulfonylurea.35 In this comparison, no difference in HbA1c 
reduction (1.11% both groups) was demonstrated between 
treatments; however, exenatide had a greater effect on 
postprandial glucose excursions than insulin glargine, which 
reduced fasting glucose to a greater extent. In a more recent 
study, Davis and colleagues investigated the substitution of 
exenatide for insulin in a 16-week study in adults with T2DM 
(BMI  27 but  40 kg/m2) using oral antidiabetic agents 
plus insulin.36 In this trial, patients using some level of insulin 
(NPH, glargine, ultralente, a mix product, or multiple insulin 
formulations) were included. A 2:1 randomization resulted in 
33 subjects switched from their insulin to exenatide (5 µg bid × 
4 weeks, then 10 µg bid × next 12 weeks) and 16 subjects 
continuing their insulin regimen. All subjects continued pre-
vious oral antidiabetic medications. In the intention to treat 
analysis, 62% of subjects switched to exenatide maintained 
glycemic control (HbA1c increase 0.5%) as compared to 
81% of the insulin treated group. Subjects in the exenatide 
group (n = 18) who had the greatest improvement were those 
using less insulin, having shorter diabetes duration, higher 
c-peptide levels, and on insulin for shorter duration. Of the 
11 exenatide-treated subjects who did not maintain glycemic 
control, 5 discontinued exenatide prior to completing the 
study period, primarily due to loss of glucose control. Overall, 
the differences in glycemic control between the two groups 
were not statistically significant. Gastrointestinal adverse 
events were reported in higher frequency for the exenatide. 
In particular, 79% of exenatide subjects reported a treatment-
emergent adverse event (48.5% nausea) compared to 56% of 
the insulin group (31.3% headache, 12.5% nausea). Incidence 
of hypoglycemia was similar between groups (39% exenatide 
and 38% insulin), primarily occurring during the daytime and 
in those using a sulfonylurea. Although this study suggests 
the possibility of replacing insulin with exenatide, it is 
difficult to fully assess the benefit of this approach given the 
high drop-out rate in the exenatide group. In addition, the 
inclusion of all insulin use in this study clouds the ability to 
discern the true benefit of substitution therapy given that the 
action of twice daily exenatide, the formulation used in the 
study, is directed more at prandial control than basal.
In an open-label crossover study comparing exenatide to 
titrated glargine in 138 adults with previously uncontrolled 
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diabetes on metformin (55.1%) or a sulfonylurea (44.9%), 
Barnett and colleagues found that both exenatide and glargine 
were associated with similar reductions in HbA1c (-1.36% 
each medication, P  0.001) with no significant difference in 
the proportion of patients achieving the American Diabetes 
Association (ADA) target HbA1c 7%.37
In a multi-country randomized trial, biphasic insulin 
aspart (ie premixed insulin, 70/30) twice daily was compared 
to twice daily exenatide in a 52-week non-inferiority study 
(n = 501, intention to treat) in overweight or obese patients 
(BMI baseline 30.4 kg/m2) suboptimally controlled (HbA1c 
greater than or equal to 7% but less than or equal to 11%) on 
metformin and a sulfonylurea.38 Following randomization, 
subjects in the exenatide group were titrated to 10 µg twice 
daily exenatide over 1 month. Premixed insulin aspart was 
initiated for the comparator group by investigators and then 
titrated on an as needed basis to achieve optimal glycemic 
control, however, a forced titration was not used to guide 
dosing. Results demonstrated non-inferiority of the exena-
tide to premixed insulin (HbA1c -1.04% ± 0.07% exenatide 
and -0.89% ± 0.06% biphasic insulin aspart, P = 0.067). 
A secondary finding was a significant reduction in weight 
with mean change from baseline of -2.5 kg and +2.9 kg for 
exenatide and premixed insulin, respectively, resulting in a 
between group difference at week 52 (-5.4 kg, P  0.001).
A second comparison of exenatide to 70/30 biphasic 
insulin aspart was recently published by Bergenstal et al.39 
In this study, adult subjects taking metformin and a sulfo-
nylurea with HbA1c  8% were randomized to either once 
or twice daily biphasic aspart or exenatide (1:1:1, N = 372). 
Glycemic control was significantly improved in the two 
groups using biphasic aspart as compared to those receiving 
exenatide (HbA1c difference of -0.91%, CI -1.23% to -0.59% 
for biphasic aspart twice daily; -0.67% reduction, CI -0.99% 
to -0.34% biphasic aspart once daily) although hypoglycemia 
was less frequent for the exenatide study group (56%, 61%, 
29% for biphasic aspart once daily, twice daily, and exenatide, 
respectively). Weight gain of 2.85 to 4.08 kg occurred in the 
insulin groups with an average weight loss of 1.96 kg in the 
exenatide group. Of note, the baseline HbA1c was 10.2% in 
this trial with mean duration of diabetes of almost 9 years, 
indicating the potential for greater need or benefit from 
insulin over exenatide therapy for these subjects.
In addition to effects on HbA1c, weight change has been 
evaluated in insulin comparative trials. In a pooled post-hoc 
analysis of two multicenter, randomized, open-label trials 
(N = 1047) comparing exenatide to insulin (glargine or 
biphasic insulin aspart) in individuals using metformin and 
a sulfonylurea, weight loss (a secondary outcome of these 
trials) was achieved in the exenatide group (73% averag-
ing 3 kg loss, 22% achieving 5% or more weight loss) as 
compared to the insulin group in which 76% of subjects 
gained weight (mean 3 kg) with only 2% achieving 5% or 
more weight loss.40 This study highlights the potential benefit 
of weight loss in exenatide users, however, strict interpreta-
tion is difficult given the post-hoc design.
exenatide vs oral DM therapies
In patients using oral antihyperglycemic therapies for 
T2DM, exenatide is an adjunctive therapy option to add to 
pre-existing metformin therapy with or without a sulfo-
nylurea. Recently, exenatide has been studied as adjunctive 
therapy to metformin with or without a thiazolidinedione 
(TZD), TZD monotherapy, and compared with sitagliptin, 
a DPP-4 inhibitor. A 2-week study of exenatide titrated to 
10 µg twice daily in adults (N = 17) vs placebo (N = 13), 
added to metformin (63%) or metformin plus a thiazoli-
dinedione (37%) further explored exenatide as adjunctive 
therapy.41 After the 2-week treatment period, 24-hour 
glucoses averaged 126 mg/dL (±3.6) and 157 mg/dL (±5.4) 
in the exenatide and placebo groups, respectively. Significant 
differences (P  0.001) between groups were noted for 
2-hour postprandial values at all meal times (119 vs 216, 
158 vs 213, and 122 vs 204 mg/dL), with triglyceride excur-
sions significantly reduced after morning and evening meals 
for the exenatide group. This study highlights the impact on 
postprandial glucose of this therapy when used as an adjunct. 
In a randomized, placebo-controlled evaluation of exenatide 
adjunctive therapy with thiazolidinedione (TZD) treatment 
for 16 weeks in 233 subjects (ages 21 to 75 years, stabilized 
on TZD for at least 4 months) from Canada, Spain, and the 
United States using either metformin or no other therapy, 
HbA1c was reduced by an additional 0.98% (95% CI -1.21% 
to -0.74%).42 In addition to HbA1c reduction with adjunctive 
therapy, weight reduction of a mean of 1.75 kg (CI -2.15 
to -0.88 kg) or 1.8% reduction occurred in the exenatide 
group. Of note, 16% of the subjects in the exenatide group 
discontinued treatment as compared to 2% in the placebo 
group due to adverse events, primarily due to nausea 
(40% exenatide vs 15% placebo). In a 2-week crossover trial, 
exenatide was compared to sitagliptin as adjunctive therapy 
to metformin with significantly improved exenatide efficacy 
on all measures including postprandial glucose lowering 
(mean 133 ± 6 exenatide vs 208 ± 6 sitagliptin mg/dL, 
P  0.00001), increased insulin secretion, reduced postpran-
dial glucagon secretion, reduced postprandial triglycerides, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 142
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slower gastric emptying, and reduced calorie intake.43 Given 
the more targeted action of exenatide at mimicking glucagon-
like peptide(GLP-1) compared with sitagliptin which impairs 
breakdown of GLP-1, these results are to be expected.
Beta cell function
Research on exenatide suggests a beneficial effect on first 
and second phase insulin secretion.44 Two recent studies 
have explored this potential using measurement and simula-
tion of beta cell function. These studies have been included 
in this update to provide evidence on the potential benefit 
of exenatide on beta cell function when used as adjunctive 
therapy.
In a 52-week study evaluating the effect on beta cell 
function of the addition of exenatide or insulin glargine 
to ongoing metformin therapy, change in blood glucose 
and C-peptide secretion in 60 subjects was measured prior 
to, at 52-weeks, and after a 4-week off-treatment period.45 
Baseline HbA1c ranged from 7.6% (±0.1) for the exenatide 
group to 7.4% (±0.1) for the glargine group. Although HbA1c 
reductions were similar for exenatide and glargine groups 
(-0.8% ± 0.1% and -0.7% ± 0.2%, respectively, at 52 weeks, 
P = 0.55), parameters of beta cell function were improved 
in the exenatide group significantly as compared to the 
glargine group. In particular, first and second phase C-peptide 
secretion were increased 1.53 (±0.11) and 2.85 ± 0.22 fold, 
respectively (P  0.00001). Of note, measures of beta cell 
function returned to pre-treatment levels by 4 weeks after 
treatment discontinuation, implying a benefit only while 
drug is present.
A second evaluation used mathematical modeling 
from data in an exenatide adjunctive therapy investigation 
to examine the effect of exenatide on predicted insulin 
secretion and beta cell function in adults with T2DM 
treated with metformin or metformin and a sulfonylurea.46 
Using data from mealtime blood glucose tests at baseline 
and week 30 for the model, an increase in insulin secretion 
was predicted for exenatide 10 µg (72% predicted increase, 
P = 0.015) and a slightly less profound increase predicted 
for 5 mcg doses (40% predicted increase, P = 0.045). 
These authors suggest the effect of exenatide on improved 
beta-cell function in their concluding remarks; however, it 
is difficult to draw specific conclusions given the theoreti-
cal nature of the model. This early work suggests a novel 
benefit of exenatide in those with T2DM not yet seen with 
other DM medications; however, further research to tease 
out the specific influence of exenatide on beta cell function 
and potential recovery is needed.
emerging research
At the 2008 meetings of the ADA and AACE, new research 
yet unpublished but available in abstract form highlighted 
novel dosage forms of exenatide (intranasal),47 positive 
effects of exenatide on post-meal metabolism and lipid 
response,48 and a beneficial influence of exenatide treatment 
on liver enzymes.49
Summary
Exenatide is a GLP-1 agonist administered as a 5 µg or 
10 µg dose subcutaneously twice daily which promotes 
satiety, post-meal glucagon suppression, and insulin release 
in response to meals. Collectively, these actions result in 
improved post-meal hyperglycemia, overall HbA1c control, 
and some degree of weight loss. In clinical trials of adults 
with T2DM, significant reductions in serum glucose and 
weight have been demonstrated for exenatide with primary 
glycemic effects of the twice daily formulation on prandial 
glucose control. Based on clinical trials, efficacy of exena-
tide appears more optimal in those who have not had long 
diabetes duration and those who have adequate endogenous 
insulin. Recent research with exenatide demonstrates ongo-
ing benefit on glycemic control and weight reduction with 
continued therapy up to 82 weeks’ duration. Additionally, 
studies have demonstrated efficacy of exenatide as adjunctive 
therapy for patients taking metformin, thiazolidinediones, 
and/or a sulfonylurea. As compared to sitagliptin, exenatide 
has superior efficacy. Compared with insulin, exenatide likely 
has greatest benefit for those patients who are overweight 
or who need improved prandial glucose control; however 
additional study is warranted to fully distinguish the role 
of exenatide versus insulin. The new long-acting release 
formulation of exenatide has demonstrated slightly improved 
efficacy compared with the twice daily formulation as well as 
a reduction in gastrointestinal side effects. The influence of 
exenatide on beta cell recovery requires further investigation; 
however, the initial studies demonstrate improved insulin 
secretion in the presence of exenatide. Emerging research 
is further exploring novel benefits of exenatide as adjunc-
tive T2DM therapy including effects on prandial glycemic 
control and markers of hepatic inflammation. Additionally, 
alternative dosage forms including intra-nasal exenatide are 
under investigation.
Conclusion
Exenatide is an effective option as adjunctive therapy for 
T2DM in those taking metformin, sulfonylureas, thiazoli-
dinediones, or insulin. The benefit appears greatest for Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 143
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individuals with inadequate prandial glycemic control or for 
whom weight reduction is desired. The use of exenatide has 
been limited by gastrointestinal side effects, cost, and the 
need for twice daily subcutaneous injection. Gastrointestinal 
side effects and the need for frequent injections may be abated 
somewhat with use of the long-acting release, once weekly 
formulation if it becomes available. Further research on the 
potential effects of exenatide on beta cell proliferation is 
needed to distinguish the benefits of therapy on insulin secre-
tion, which has been demonstrated, versus insulin production 
or beta cell recovery.
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